Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

Inclusion Criteria:

* Documented relapsed or refractory B-cell NHL; CD-20 positive tumor. Indolent NHL: follicular B-cell lymphoma, diffuse small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, transformed aggressive lymphomas, mantle cell lymphoma and chronic lymphocytic leukemia
* Maximum of 6 prior chemotherapy regimens. Prior rituximab is allowed.
* Bidimensionally measurable disease
* ECOG performance status 0-2
* Absolute neutrophil count \>/= 1000 and platelet count \>/= 50,000
* Serum creatinine \</= 1.5 mg/dL
* Adequate hepatic function
* Estimated life expectancy of at least 3 months
* All study participants must be registered into the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssist
* Able to take aspirin 81 mg daily as prophylactic anticoagulation

Exclusion Criteria:

* Chemotherapy or immunotherapy within 3 weeks prior to entering study or failure to recover from adverse events due to any agents administered previously
* Use of investigational agents within 28 days of study
* Hematopoietic growth factors within 14 days of study
* History of prior high dose chemotherapy with allogeneic stem cell support
* History of prior radioimmunotherapy \</= 1 year
* Concurrent treatment with therapeutic doses of systemic steroids
* Pregnant or lactating female subjects
* Concurrent, active malignancy other than lymphoma or CLL
* Primary CNS lymphoma
* Patients with a prior diagnosis of lymphoma active in the CNS are eligible only if CNS has been treated, and they are neurologically stable with no progressive symptoms off steroids and anti-convulsants
* Serious infection, medical condition, or psychiatric condition that, in the opinion of the investigator, might interfere with the achievement of study objectives
* Hypersensitivity to murine proteins or to any component of rituximab
* Known positive for HIV or infectious hepatitis type C; hepatitis type B that is active and uncontrolled
* Hypersensitivity to mannitol
* Evidence of laboratory tumor lysis syndrome by Cairo-Bishop criteria
* Subject with recent thromboembolic event (deep vein thrombosis or pulmonary embolism) unless clinically stable and event occurred more than 2 weeks prior to enrollment.